Galaxy Biomedical Investment Co., Ltd. announced earnings results for the nine months ended September 30, 2020. For the nine months, the company announced sales was CNY 802.232 million compared to CNY 478.483 million a year ago. Operating income was CNY 53.441 million compared to operating loss of CNY 115.900 million a year ago. Net income was CNY 35.300 million compared to net loss of CNY 108.374 million a year ago. Basic earnings per share from continuing operations was CNY 0.0321 compared to basic loss per share from continuing operations of CNY 0.0985 a year ago.